Perioperative therapy for resectable liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of treatments before and after surgery for liver cancer that can be removed. The goal is to see if adding targeted therapy and immunotherapy can reduce the risk of cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have been diagnosed with hepatocellular carcinoma (the most common type of liver cancer) that is considered resectable (removable by surgery).
- Your liver function is good (Child-Pugh class A).
- You have not had prior systemic treatment (e.g., chemotherapy, targeted therapy, immunotherapy) for this cancer.
- You are generally able to take care of yourself (ECOG 0-1) and expected to live at least 12 months.
- You do not have other significant health conditions such as uncontrolled heart disease, active infections, or autoimmune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether giving lenvatinib and immunotherapy along with TACE (a liver artery treatment) before surgery can lower the risk of hepatocellular carcinoma coming back after surgery. It targets people with certain higher-risk early-stage liver tumors (CNLC IB/IIA).
This trial tests whether giving pembrolizumab (an immune therapy) and lenvatinib (a targeted pill) before planned liver surgery can improve outcomes for people with certain types of operable hepatocellular carcinoma (HCC). It’s meant for tumors that can be removed with curative intent, but still carry a risk of coming back.
This trial tests whether adding a liver-directed treatment to standard systemic therapy can improve outcomes for people with liver cancer that cannot be removed. It may help shrink tumors or slow the disease while on current treatment.
This trial tests whether giving a combination of chemotherapy, immunotherapy, and targeted therapy before surgery can shrink liver cancer and reduce the chance of it coming back, compared to going straight to surgery. The treatment includes medicines like pembrolizumab (sintilimab) and a drug that blocks blood vessel growth (bevacizumab).
This trial combines surgery to remove liver tumors with two drugs, camrelizumab (an immunotherapy that helps your immune system fight cancer) and apatinib (a targeted therapy that may cut off the tumor's blood supply). It aims to see if this combination helps people with advanced liver cancer that has spread outside the liver (but not to the brain) and who have chosen not to have other standard treatments like TACE or radiation. Participating could potentially control the spreading cancer and improve outcomes.
This study combines a liver-directed procedure called TACE (which blocks blood flow to the tumor and delivers chemotherapy directly to it) with two immunotherapy drugs and a targeted therapy (bevacizumab). The goal is to see if this combination can shrink liver cancer that cannot be surgically removed, without the cancer having spread elsewhere.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.